EDB domain of fibronectin — Drug Target

All drugs that target EDB domain of fibronectin — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Immunocytokine

Phase 2 pipeline (1)

• Intratumoral injections of L19IL2 · Philogen S.p.A. · Immunocytokine · Oncology
  L19IL2 is an immunocytokine that targets the EDB domain of fibronectin, which is overexpressed in tumor vasculature, and delivers IL-2 to the tumor microenvironment to stimulate an anti-tumor immune response.